The latest price target for Cartesian Therapeutics (NASDAQ:RNAC) was reported by Needham on April 9, 2025. The analyst firm set a price target for $41.00 expecting RNAC to rise to within 12 months (a possible 281.40% upside). 31 analyst firms have reported ratings in the last year.

The latest analyst rating for Cartesian Therapeutics (NASDAQ:RNAC) was provided by Needham, and Cartesian Therapeutics reiterated their buy rating.

There is no last upgrade for Cartesian Therapeutics

The last downgrade for Cartesian Therapeutics Inc happened on July 2, 2024 when Oppenheimer changed their price target from N/A to N/A for Cartesian Therapeutics Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Cartesian Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Cartesian Therapeutics was filed on April 9, 2025 so you should expect the next rating to be made available sometime around April 9, 2026.

While ratings are subjective and will change, the latest Cartesian Therapeutics (RNAC) rating was a reiterated with a price target of $41.00 to $41.00. The current price Cartesian Therapeutics (RNAC) is trading at is $10.75, which is out of the analyst’s predicted range.